Clinical trial
Medications for the Treatment of Dysthymic Disorder and Double Depression
NCT00234312 · Oregon Health and Science University, Other · Completed
Key facts
| NCT number | NCT00234312 |
|---|---|
| Title | Medications for the Treatment of Dysthymic Disorder and Double Depression |
| Official title | Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression |
| Lead sponsor | Oregon Health and Science University, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Depression, Dysthymia |
| Intervention type | Drug |
| Interventions | escitalopram and sertraline |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Oct 6, 2005 |
| Last update posted | Jul 29, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: